Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics
•Individuals with intellectually disability frequently use long-term antipsychotics.•Chronic use of these agents may have detrimental effects on health.•We investigated presence and determinants of antipsychotics-related health symptoms.•Extrapyramidal symptoms were present in 53% and overweight in...
Gespeichert in:
Veröffentlicht in: | Research in developmental disabilities 2013-09, Vol.34 (9), p.2799-2809 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2809 |
---|---|
container_issue | 9 |
container_start_page | 2799 |
container_title | Research in developmental disabilities |
container_volume | 34 |
creator | de Kuijper, Gerda Mulder, Hans Evenhuis, Heleen Scholte, Frans Visser, Frank Hoekstra, Pieter J. |
description | •Individuals with intellectually disability frequently use long-term antipsychotics.•Chronic use of these agents may have detrimental effects on health.•We investigated presence and determinants of antipsychotics-related health symptoms.•Extrapyramidal symptoms were present in 53% and overweight in 46%.•Use of atypical antipsychotics was related to elevated glucose and blood pressure.
Individuals with intellectual disability frequently use antipsychotics for many years. This may have detrimental health effects, including neurological symptoms and metabolic and hormonal dysregulation, the latter possibly affecting bone metabolism. There is large variability in the degree in which antipsychotic agents lead to these health problems. In the current study we investigated potential determinants of physical symptoms and biological parameters known to be associated with use of antipsychotics in a convenience sample of 99 individuals with intellectual disability who had used antipsychotics for more than one year for behavioural symptoms. We focused on extrapyramidal symptoms; on overweight and presence of components of the metabolic syndrome; and on elevated plasma prolactin and bone turnover parameters. As predictor variables, we used patient (sex, age, genetic polymorphisms, and severity of intellectual disability) and medication use (type and dosage) characteristics. We found extrapyramidal symptoms to be present in 53%, overweight or obesity in 46%, and the metabolic syndrome in 11% of participants. Hyperprolactineaemia and one or more elevated bone turnover markers were present in 17% and 25%, respectively. Higher age and more severe intellectual disability were associated with dyskinesia and a higher dosage of the antipsychotic drug was associated with parkinsonism. Less severe intellectual disability was related to higher Body Mass Index. Use of atypical antipsychotics was associated with higher diastolic blood pressure and elevated fasting glucose. Clinicians who prescribe antipsychotics in individuals with intellectual disability should carefully balance the potential benefits of prolonged treatment against the risk of health hazards associated with the use of antipsychotics. |
doi_str_mv | 10.1016/j.ridd.2013.05.016 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1541980946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S089142221300200X</els_id><sourcerecordid>1411633067</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-3c26af15b96ec3221bd90b07d58d20f9070ba5e5422ab7045c11502226399d823</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EokvhD3BAviBxSeqPJI4lLqiFUqlSL-VsObZDZpUv7KSr_fdMtAvcimzJ0swz78z4JeQ9ZzlnvLra5xG8zwXjMmdljqEXZMdrJTMplX5JdqzWPCuEEBfkTUp7xrjC85pcCMyLQugdOdyEJcQBRjsuiU4tnbtjAmd72gXbLx2dbbTDxiQKI14PT-BX2yd6AEzDuIS-D27BEPWQbAM9LEd66Ca6pkD7afyZbR0oNoA5HV03LeDSW_KqRZHw7vxekh_fvj5ef8_uH27vrr_cZ67gesmkE5VtednoKjgpBG-8Zg1Tvqy9YK1mijW2DCUuaRvFitJxXjLcuJJa-1rIS_LppDvH6dca0mIGSA5HtmOY1mR4iX1qpovq_2jBeSUlqxSi4oS6OKUUQ2vmCIONR8OZ2bwxe7N5YzZvDCsNhrDow1l_bYbg_5b8MQOBj2fAJnSgjXZ0kP5xqhJK1xK5zycu4Mc9QYgmOQijCx4iOmH8BM_N8Rv4Ba4s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1411633067</pqid></control><display><type>article</type><title>Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><creator>de Kuijper, Gerda ; Mulder, Hans ; Evenhuis, Heleen ; Scholte, Frans ; Visser, Frank ; Hoekstra, Pieter J.</creator><creatorcontrib>de Kuijper, Gerda ; Mulder, Hans ; Evenhuis, Heleen ; Scholte, Frans ; Visser, Frank ; Hoekstra, Pieter J.</creatorcontrib><description>•Individuals with intellectually disability frequently use long-term antipsychotics.•Chronic use of these agents may have detrimental effects on health.•We investigated presence and determinants of antipsychotics-related health symptoms.•Extrapyramidal symptoms were present in 53% and overweight in 46%.•Use of atypical antipsychotics was related to elevated glucose and blood pressure.
Individuals with intellectual disability frequently use antipsychotics for many years. This may have detrimental health effects, including neurological symptoms and metabolic and hormonal dysregulation, the latter possibly affecting bone metabolism. There is large variability in the degree in which antipsychotic agents lead to these health problems. In the current study we investigated potential determinants of physical symptoms and biological parameters known to be associated with use of antipsychotics in a convenience sample of 99 individuals with intellectual disability who had used antipsychotics for more than one year for behavioural symptoms. We focused on extrapyramidal symptoms; on overweight and presence of components of the metabolic syndrome; and on elevated plasma prolactin and bone turnover parameters. As predictor variables, we used patient (sex, age, genetic polymorphisms, and severity of intellectual disability) and medication use (type and dosage) characteristics. We found extrapyramidal symptoms to be present in 53%, overweight or obesity in 46%, and the metabolic syndrome in 11% of participants. Hyperprolactineaemia and one or more elevated bone turnover markers were present in 17% and 25%, respectively. Higher age and more severe intellectual disability were associated with dyskinesia and a higher dosage of the antipsychotic drug was associated with parkinsonism. Less severe intellectual disability was related to higher Body Mass Index. Use of atypical antipsychotics was associated with higher diastolic blood pressure and elevated fasting glucose. Clinicians who prescribe antipsychotics in individuals with intellectual disability should carefully balance the potential benefits of prolonged treatment against the risk of health hazards associated with the use of antipsychotics.</description><identifier>ISSN: 0891-4222</identifier><identifier>EISSN: 1873-3379</identifier><identifier>DOI: 10.1016/j.ridd.2013.05.016</identifier><identifier>PMID: 23792429</identifier><identifier>CODEN: RDDIEF</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ltd</publisher><subject>Adult ; Adult and adolescent clinical studies ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - adverse effects ; Antipsychotic drugs ; Antipsychotics ; Basal Ganglia Diseases - chemically induced ; Basal Ganglia Diseases - epidemiology ; Basal Ganglia Diseases - genetics ; Biological and medical sciences ; Biomarkers ; Blood Glucose - drug effects ; Blood Pressure - drug effects ; Bone and Bones - metabolism ; Bone markers ; Bones ; Determinants ; Extrapyramidal symptoms ; Female ; Genetic polymorphisms ; Health Status ; Humans ; Intellectual deficiency ; Intellectual disability ; Intellectual Disability - drug therapy ; Intellectual Disability - epidemiology ; Intellectual Disability - genetics ; Learning disabilities ; Long-term use ; Male ; Medical sciences ; Metabolic symptoms ; Metabolic Syndrome - chemically induced ; Metabolic Syndrome - epidemiology ; Metabolic Syndrome - genetics ; Middle Aged ; Nervous system (semeiology, syndromes) ; Nervous system as a whole ; Neurology ; Neuropharmacology ; Obesity ; Overweight - chemically induced ; Overweight - epidemiology ; Overweight - genetics ; Parameters ; Pharmacology. Drug treatments ; Polymorphism, Genetic ; Prolactin - blood ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Risk Factors ; Symptoms</subject><ispartof>Research in developmental disabilities, 2013-09, Vol.34 (9), p.2799-2809</ispartof><rights>2013 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-3c26af15b96ec3221bd90b07d58d20f9070ba5e5422ab7045c11502226399d823</citedby><cites>FETCH-LOGICAL-c419t-3c26af15b96ec3221bd90b07d58d20f9070ba5e5422ab7045c11502226399d823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ridd.2013.05.016$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,30981,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27627983$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23792429$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Kuijper, Gerda</creatorcontrib><creatorcontrib>Mulder, Hans</creatorcontrib><creatorcontrib>Evenhuis, Heleen</creatorcontrib><creatorcontrib>Scholte, Frans</creatorcontrib><creatorcontrib>Visser, Frank</creatorcontrib><creatorcontrib>Hoekstra, Pieter J.</creatorcontrib><title>Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics</title><title>Research in developmental disabilities</title><addtitle>Res Dev Disabil</addtitle><description>•Individuals with intellectually disability frequently use long-term antipsychotics.•Chronic use of these agents may have detrimental effects on health.•We investigated presence and determinants of antipsychotics-related health symptoms.•Extrapyramidal symptoms were present in 53% and overweight in 46%.•Use of atypical antipsychotics was related to elevated glucose and blood pressure.
Individuals with intellectual disability frequently use antipsychotics for many years. This may have detrimental health effects, including neurological symptoms and metabolic and hormonal dysregulation, the latter possibly affecting bone metabolism. There is large variability in the degree in which antipsychotic agents lead to these health problems. In the current study we investigated potential determinants of physical symptoms and biological parameters known to be associated with use of antipsychotics in a convenience sample of 99 individuals with intellectual disability who had used antipsychotics for more than one year for behavioural symptoms. We focused on extrapyramidal symptoms; on overweight and presence of components of the metabolic syndrome; and on elevated plasma prolactin and bone turnover parameters. As predictor variables, we used patient (sex, age, genetic polymorphisms, and severity of intellectual disability) and medication use (type and dosage) characteristics. We found extrapyramidal symptoms to be present in 53%, overweight or obesity in 46%, and the metabolic syndrome in 11% of participants. Hyperprolactineaemia and one or more elevated bone turnover markers were present in 17% and 25%, respectively. Higher age and more severe intellectual disability were associated with dyskinesia and a higher dosage of the antipsychotic drug was associated with parkinsonism. Less severe intellectual disability was related to higher Body Mass Index. Use of atypical antipsychotics was associated with higher diastolic blood pressure and elevated fasting glucose. Clinicians who prescribe antipsychotics in individuals with intellectual disability should carefully balance the potential benefits of prolonged treatment against the risk of health hazards associated with the use of antipsychotics.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic drugs</subject><subject>Antipsychotics</subject><subject>Basal Ganglia Diseases - chemically induced</subject><subject>Basal Ganglia Diseases - epidemiology</subject><subject>Basal Ganglia Diseases - genetics</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Pressure - drug effects</subject><subject>Bone and Bones - metabolism</subject><subject>Bone markers</subject><subject>Bones</subject><subject>Determinants</subject><subject>Extrapyramidal symptoms</subject><subject>Female</subject><subject>Genetic polymorphisms</subject><subject>Health Status</subject><subject>Humans</subject><subject>Intellectual deficiency</subject><subject>Intellectual disability</subject><subject>Intellectual Disability - drug therapy</subject><subject>Intellectual Disability - epidemiology</subject><subject>Intellectual Disability - genetics</subject><subject>Learning disabilities</subject><subject>Long-term use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic symptoms</subject><subject>Metabolic Syndrome - chemically induced</subject><subject>Metabolic Syndrome - epidemiology</subject><subject>Metabolic Syndrome - genetics</subject><subject>Middle Aged</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Nervous system as a whole</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Obesity</subject><subject>Overweight - chemically induced</subject><subject>Overweight - epidemiology</subject><subject>Overweight - genetics</subject><subject>Parameters</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymorphism, Genetic</subject><subject>Prolactin - blood</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Risk Factors</subject><subject>Symptoms</subject><issn>0891-4222</issn><issn>1873-3379</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqFkU1v1DAQhi0EokvhD3BAviBxSeqPJI4lLqiFUqlSL-VsObZDZpUv7KSr_fdMtAvcimzJ0swz78z4JeQ9ZzlnvLra5xG8zwXjMmdljqEXZMdrJTMplX5JdqzWPCuEEBfkTUp7xrjC85pcCMyLQugdOdyEJcQBRjsuiU4tnbtjAmd72gXbLx2dbbTDxiQKI14PT-BX2yd6AEzDuIS-D27BEPWQbAM9LEd66Ca6pkD7afyZbR0oNoA5HV03LeDSW_KqRZHw7vxekh_fvj5ef8_uH27vrr_cZ67gesmkE5VtednoKjgpBG-8Zg1Tvqy9YK1mijW2DCUuaRvFitJxXjLcuJJa-1rIS_LppDvH6dca0mIGSA5HtmOY1mR4iX1qpovq_2jBeSUlqxSi4oS6OKUUQ2vmCIONR8OZ2bwxe7N5YzZvDCsNhrDow1l_bYbg_5b8MQOBj2fAJnSgjXZ0kP5xqhJK1xK5zycu4Mc9QYgmOQijCx4iOmH8BM_N8Rv4Ba4s</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>de Kuijper, Gerda</creator><creator>Mulder, Hans</creator><creator>Evenhuis, Heleen</creator><creator>Scholte, Frans</creator><creator>Visser, Frank</creator><creator>Hoekstra, Pieter J.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QJ</scope></search><sort><creationdate>20130901</creationdate><title>Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics</title><author>de Kuijper, Gerda ; Mulder, Hans ; Evenhuis, Heleen ; Scholte, Frans ; Visser, Frank ; Hoekstra, Pieter J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-3c26af15b96ec3221bd90b07d58d20f9070ba5e5422ab7045c11502226399d823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic drugs</topic><topic>Antipsychotics</topic><topic>Basal Ganglia Diseases - chemically induced</topic><topic>Basal Ganglia Diseases - epidemiology</topic><topic>Basal Ganglia Diseases - genetics</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Pressure - drug effects</topic><topic>Bone and Bones - metabolism</topic><topic>Bone markers</topic><topic>Bones</topic><topic>Determinants</topic><topic>Extrapyramidal symptoms</topic><topic>Female</topic><topic>Genetic polymorphisms</topic><topic>Health Status</topic><topic>Humans</topic><topic>Intellectual deficiency</topic><topic>Intellectual disability</topic><topic>Intellectual Disability - drug therapy</topic><topic>Intellectual Disability - epidemiology</topic><topic>Intellectual Disability - genetics</topic><topic>Learning disabilities</topic><topic>Long-term use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic symptoms</topic><topic>Metabolic Syndrome - chemically induced</topic><topic>Metabolic Syndrome - epidemiology</topic><topic>Metabolic Syndrome - genetics</topic><topic>Middle Aged</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Nervous system as a whole</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Obesity</topic><topic>Overweight - chemically induced</topic><topic>Overweight - epidemiology</topic><topic>Overweight - genetics</topic><topic>Parameters</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymorphism, Genetic</topic><topic>Prolactin - blood</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Risk Factors</topic><topic>Symptoms</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Kuijper, Gerda</creatorcontrib><creatorcontrib>Mulder, Hans</creatorcontrib><creatorcontrib>Evenhuis, Heleen</creatorcontrib><creatorcontrib>Scholte, Frans</creatorcontrib><creatorcontrib>Visser, Frank</creatorcontrib><creatorcontrib>Hoekstra, Pieter J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><jtitle>Research in developmental disabilities</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Kuijper, Gerda</au><au>Mulder, Hans</au><au>Evenhuis, Heleen</au><au>Scholte, Frans</au><au>Visser, Frank</au><au>Hoekstra, Pieter J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics</atitle><jtitle>Research in developmental disabilities</jtitle><addtitle>Res Dev Disabil</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>34</volume><issue>9</issue><spage>2799</spage><epage>2809</epage><pages>2799-2809</pages><issn>0891-4222</issn><eissn>1873-3379</eissn><coden>RDDIEF</coden><abstract>•Individuals with intellectually disability frequently use long-term antipsychotics.•Chronic use of these agents may have detrimental effects on health.•We investigated presence and determinants of antipsychotics-related health symptoms.•Extrapyramidal symptoms were present in 53% and overweight in 46%.•Use of atypical antipsychotics was related to elevated glucose and blood pressure.
Individuals with intellectual disability frequently use antipsychotics for many years. This may have detrimental health effects, including neurological symptoms and metabolic and hormonal dysregulation, the latter possibly affecting bone metabolism. There is large variability in the degree in which antipsychotic agents lead to these health problems. In the current study we investigated potential determinants of physical symptoms and biological parameters known to be associated with use of antipsychotics in a convenience sample of 99 individuals with intellectual disability who had used antipsychotics for more than one year for behavioural symptoms. We focused on extrapyramidal symptoms; on overweight and presence of components of the metabolic syndrome; and on elevated plasma prolactin and bone turnover parameters. As predictor variables, we used patient (sex, age, genetic polymorphisms, and severity of intellectual disability) and medication use (type and dosage) characteristics. We found extrapyramidal symptoms to be present in 53%, overweight or obesity in 46%, and the metabolic syndrome in 11% of participants. Hyperprolactineaemia and one or more elevated bone turnover markers were present in 17% and 25%, respectively. Higher age and more severe intellectual disability were associated with dyskinesia and a higher dosage of the antipsychotic drug was associated with parkinsonism. Less severe intellectual disability was related to higher Body Mass Index. Use of atypical antipsychotics was associated with higher diastolic blood pressure and elevated fasting glucose. Clinicians who prescribe antipsychotics in individuals with intellectual disability should carefully balance the potential benefits of prolonged treatment against the risk of health hazards associated with the use of antipsychotics.</abstract><cop>Amsterdam</cop><pub>Elsevier Ltd</pub><pmid>23792429</pmid><doi>10.1016/j.ridd.2013.05.016</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0891-4222 |
ispartof | Research in developmental disabilities, 2013-09, Vol.34 (9), p.2799-2809 |
issn | 0891-4222 1873-3379 |
language | eng |
recordid | cdi_proquest_miscellaneous_1541980946 |
source | MEDLINE; Elsevier ScienceDirect Journals; Applied Social Sciences Index & Abstracts (ASSIA) |
subjects | Adult Adult and adolescent clinical studies Antipsychotic Agents - administration & dosage Antipsychotic Agents - adverse effects Antipsychotic drugs Antipsychotics Basal Ganglia Diseases - chemically induced Basal Ganglia Diseases - epidemiology Basal Ganglia Diseases - genetics Biological and medical sciences Biomarkers Blood Glucose - drug effects Blood Pressure - drug effects Bone and Bones - metabolism Bone markers Bones Determinants Extrapyramidal symptoms Female Genetic polymorphisms Health Status Humans Intellectual deficiency Intellectual disability Intellectual Disability - drug therapy Intellectual Disability - epidemiology Intellectual Disability - genetics Learning disabilities Long-term use Male Medical sciences Metabolic symptoms Metabolic Syndrome - chemically induced Metabolic Syndrome - epidemiology Metabolic Syndrome - genetics Middle Aged Nervous system (semeiology, syndromes) Nervous system as a whole Neurology Neuropharmacology Obesity Overweight - chemically induced Overweight - epidemiology Overweight - genetics Parameters Pharmacology. Drug treatments Polymorphism, Genetic Prolactin - blood Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Risk Factors Symptoms |
title | Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T19%3A59%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determinants%20of%20physical%20health%20parameters%20in%20individuals%20with%20intellectual%20disability%20who%20use%20long-term%20antipsychotics&rft.jtitle=Research%20in%20developmental%20disabilities&rft.au=de%20Kuijper,%20Gerda&rft.date=2013-09-01&rft.volume=34&rft.issue=9&rft.spage=2799&rft.epage=2809&rft.pages=2799-2809&rft.issn=0891-4222&rft.eissn=1873-3379&rft.coden=RDDIEF&rft_id=info:doi/10.1016/j.ridd.2013.05.016&rft_dat=%3Cproquest_cross%3E1411633067%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1411633067&rft_id=info:pmid/23792429&rft_els_id=S089142221300200X&rfr_iscdi=true |